Avient Valuation
Is PY9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PY9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PY9 (€50.5) is trading below our estimate of fair value (€60.46)
Significantly Below Fair Value: PY9 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PY9?
Key metric: As PY9 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PY9's PE Ratio? | |
|---|---|
| PE Ratio | 32.2x |
| Earnings | US$149.00m |
| Market Cap | US$4.86b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 11.7x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does PY9's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.2x | ||
WCH Wacker Chemie | 28.3x | 37.0% | €3.5b |
EVK Evonik Industries | 35.2x | 33.1% | €8.1b |
SY1 Symrise | 37.3x | 13.2% | €14.6b |
ACT AlzChem Group | 11.9x | 12.6% | €598.4m |
PY9 Avient | 32.2x | 20.4% | €4.9b |
Price-To-Earnings vs Peers: PY9 is expensive based on its Price-To-Earnings Ratio (32.2x) compared to the peer average (28.2x).
Price to Earnings Ratio vs Industry
How does PY9's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: PY9 is expensive based on its Price-To-Earnings Ratio (32.2x) compared to the European Chemicals industry average (17.1x).
Price to Earnings Ratio vs Fair Ratio
What is PY9's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32.2x |
| Fair PE Ratio | 18.7x |
Price-To-Earnings vs Fair Ratio: PY9 is expensive based on its Price-To-Earnings Ratio (32.2x) compared to the estimated Fair Price-To-Earnings Ratio (18.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €50.50 | €52.05 +3.1% | 9.6% | €60.90 | €47.06 | n/a | 5 |
| Nov ’25 | €42.40 | €52.05 +22.7% | 9.6% | €60.90 | €47.06 | n/a | 5 |
| Oct ’25 | €44.80 | €47.91 +6.9% | 5.1% | €50.35 | €43.03 | n/a | 6 |
| Sep ’25 | €44.20 | €47.91 +8.4% | 5.1% | €50.35 | €43.03 | n/a | 6 |
| Aug ’25 | €41.00 | €48.28 +17.8% | 5.7% | €51.23 | €43.78 | n/a | 6 |
| Jul ’25 | €40.40 | €48.28 +19.5% | 5.7% | €51.23 | €43.78 | n/a | 6 |
| Jun ’25 | €40.20 | €48.22 +20.0% | 5.3% | €51.01 | €43.59 | n/a | 7 |
| May ’25 | €39.80 | €43.89 +10.3% | 7.9% | €46.98 | €37.58 | n/a | 7 |
| Apr ’25 | €40.00 | €42.16 +5.4% | 7.1% | €45.48 | €37.12 | n/a | 7 |
| Mar ’25 | €37.20 | €42.16 +13.3% | 7.1% | €45.48 | €37.12 | n/a | 7 |
| Feb ’25 | €33.60 | €40.17 +19.5% | 8.9% | €44.59 | €33.67 | n/a | 7 |
| Jan ’25 | €37.60 | €40.17 +6.8% | 8.9% | €44.59 | €33.67 | n/a | 7 |
| Dec ’24 | €31.00 | €40.37 +30.2% | 9.9% | €45.70 | €34.51 | n/a | 7 |
| Nov ’24 | €29.60 | €44.42 +50.1% | 7.1% | €47.11 | €37.69 | €42.40 | 7 |
| Oct ’24 | €33.00 | €44.48 +34.8% | 7.4% | €46.89 | €37.51 | €44.80 | 7 |
| Sep ’24 | €37.40 | €43.25 +15.6% | 7.4% | €45.59 | €36.47 | €44.20 | 7 |
| Aug ’24 | €37.00 | €43.25 +16.9% | 7.4% | €45.59 | €36.47 | €41.00 | 7 |
| Jul ’24 | €37.40 | €42.61 +13.9% | 8.5% | €47.43 | €36.49 | €40.40 | 7 |
| Jun ’24 | €34.20 | €42.67 +24.8% | 8.0% | €47.21 | €36.32 | €40.20 | 8 |
| May ’24 | €34.80 | €44.35 +27.4% | 7.3% | €48.42 | €37.25 | €39.80 | 8 |
| Apr ’24 | €37.60 | €44.35 +17.9% | 7.3% | €48.42 | €37.25 | €40.00 | 8 |
| Mar ’24 | €41.00 | €44.97 +9.7% | 6.9% | €49.06 | €37.74 | €37.20 | 9 |
| Feb ’24 | €37.60 | €39.22 +4.3% | 13.0% | €46.98 | €31.94 | €33.60 | 8 |
| Jan ’24 | €31.20 | €38.38 +23.0% | 15.1% | €47.09 | €31.08 | €37.60 | 8 |
| Dec ’23 | €32.80 | €38.41 +17.1% | 17.5% | €49.88 | €31.92 | €31.00 | 8 |
| Nov ’23 | €34.40 | €45.41 +32.0% | 18.0% | €61.21 | €37.13 | €29.60 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.0b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.40
7D
-1.7%
1Y
36.5%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.05
7D
0.9%
1Y
-12.1%
African Rainbow Minerals
R31.4b
Through its subsidiaries, operates as a diversified mining and minerals company in South Africa, Malaysia, and Switzerland.
EB9
R8.40
7D
-1.8%
1Y
-3.4%